Chart review for potential features of myocarditis, pericarditis, and cardiomyopathy in children and adolescents treated with clozapine

Journal of Child and Adolescent Psychopharmacology

Volumn 14, Issue 2, 2004, Pages 267-271

  Wehmeier, Peter M ^a   Schüler Springorum, Mareike ^a   Heiser, Philip ^a   Remschmidt, Helmut ^a  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE;

ADOLESCENT; ADULT; CARDIOMYOPATHY; CLINICAL ARTICLE; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAM; FEMALE; HUMAN; MALE; MEDICAL RECORD; MYOCARDITIS; PATIENT MONITORING; PERICARDITIS; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; REVIEW; SCHOOL CHILD;

ADOLESCENT; ANTIPSYCHOTIC AGENTS; ASPARTATE AMINOTRANSFERASES; BODY TEMPERATURE; CARDIOMYOPATHIES; CHILD; CLOZAPINE; CREATINE KINASE; ELECTROCARDIOGRAPHY; FEMALE; HUMANS; L-LACTATE DEHYDROGENASE; LEUKOCYTE COUNT; MALE; MYOCARDITIS; PERICARDITIS; RETROSPECTIVE STUDIES; SCHIZOPHRENIA;

EID: 3342931111     PISSN: 10445463     EISSN: None     Source Type: Journal    
DOI: 10.1089/1044546041648977     Document Type: Review

References (29)

1. Alvir JMJ, Liberman JA: Agranulocytosis: Incidence and risk factors. J Clin Psychiatry 55(Suppl B):137-138, 1994.
2. Baker S: Myocarditis with clozapine. [Letter] Australian J Hosp Pharm 30:28-29, 2000.
3. Catalano G, Catalano MC, Wetter RLF: Clozapine-induced polyserositis. Clin Neuropharmacol 20: 352-356, 1997.
4. Committee on Safety of Medicines: Myocarditis with antipsychotics: Recent cases with clozapine (Clozaril). Curr Prob Pharmacovigilance 19:9-10, 1993.
5. Coulter DM, Bate A, Meyboom RHB, Lindquist M, Edwards IR: Antipsychotic drugs and heart muscle disorder in international pharmacovigilance: Data-mining study. Br Med J 322:1207-1209, 2001.
6. Daly JM, Goldberg RJ, Braman SS: Polyserositis associated with clozapine treatment. [Letter] Am J Psychiatry 149:1274-1275, 1992.
7. Degner D, Bleich S, Grohmann R, Bandelow B, Rüther E: Myocarditis associated with clozapine treatment. [Letter] Aust N Z J Psychiatry 34:880, 2000.
8. Devarajan S, Kutcher SP, Dursun SM: Clozapine and sudden death. [Letter] Lancet 355:841, 2000.
9. Ereshefsky L, Watanabe MD, Tran-Johnson TK: Clozapine: An atypical antipsychotic agent. Clin Pharmacol 8:691-709, 1989.
10. Hägg S, Spigset O, Bate A: Myocarditis related to clozapine treatment. J Clin Psychopharmacol 21:382-388, 2001.
11. Kang UG, Kwon JS, Ahn YM, Chung SJ, Ha JH, Koo YJ, Kim YS: Electrocardiographic abnormalities in patients treated with clozapine. J Clin Psychiatry 61:441-446, 2000.
12. Kay SE, Doery J, Sholl D: Clozapine-associated pericarditis and elevated troponin I. [Letter] Aust N Z J Psychiatry 36:143-144, 2002.
13. Kilian J, Lawrence C, Celermajer DS: Myocarditis and cardiomyopathy associated with clozapine. Lancet 354:1841-1845, 1999.
14. Koren W, Kreis Y, Duchowiczny K, Prince T, Sancovici S, Sidi Y, Gur H: Lactic acidosis and fatal myocardial failure due to clozapine. Ann Pharmacother 31:168-170, 1997.
15. La Grenade L, Graham D, Trontell A: Myocarditis and cardiomyopathy associated with clozapine use in the United States. [Letter] N Engl J Med 345:224-225, 2001.
16. Leo RJ, Kreeger JL, Kim KY: Cardiomyopathy associated with clozapine. Ann Pharmacother 30: 603-605, 1996.
17. Liberman JA, Kane JM, Johns CA: Clozapine: Guidelines for clinical management. J Clin Psychiatry 50:329-338, 1989.
18. Low RA, Fuller MA: Clozapine-induced atrial fibrillation. [Letter] J Clin Psychopharmacol 18:170, 1998.
19. Miller DD: Review and management of clozapine side effects. J Clin Psychiatry 61(Suppl 8):14-17, 2000.
20. Naber D, Holzbach R, Perro C, Hippius H: Clinical management of clozapine patients in relation to efficacy and side effects. Br J Psychiatry 160 (Suppl 17):54-59, 1992.
21. Pollmächer T, Schuld A, Kraus T, Haack M, Hinze-Selch D: Zur klinischen Relevanz der Wirkung von Clozapin auf die Freisetzung von Zytokinen und löslichen Zytokinrezeptoren. Fortschr Neurol Psychiatr 69(Suppl 2):S65-S74, 2001.
22. Remington G, Chong SA: Conventional versus novel antipsychotics: Changing concepts and clinical implications. J Psychiatry Neurosci 24: 431-432, 1999.
23. Remschmidt H, Fleischhaker C, Hennighausen K, Schulz E: Management of schizophrenia in children and adolescents. The role of clozapine. Paediatr Drugs 2:253-262, 2000.
24. Safferman A, Liberman J, Kane J, Szymansky S, Kinon B: Update on the clinical efficacy and side effects of clozapine. Schizophr Bull 17:247-261, 1991.
25. Sticht G, Käferstein H, Henßge C: Befunde bei chronischer Einnahme und akuter Überdosierung von Leponex®. Beitr Gerichtl Med 67:81-86, 1988.
26. Toren P, Laor N, Weizman A: Use of atypical neuroleptics in child and adolescent psychiatry. J Clin Psychiatry 59:644-656, 1998.
27. Walker AM, Lanza LL, Arellano F, Rothman KJ: Mortality in current and former users of clozapine. Epidemiology 8:671-677, 1997.
28. Wehmeier PM, Heiser P, Remschmidt H: Pancreatitis followed by pericardial effusion in an adolescent treated with clozapine. [Letter] J Clin Psychopharmacol 23:102-103, 2003.
29. Worm K, Kringsholm B, Steentoft A: Clozapine cases with fatal, toxic, or therapeutic concentrations. Int J Legal Med 106:115-118, 1993.